See What HealthDay Can Do For You
Contact Us

Self-Reported Eczema Valid for Detecting Atopic Dermatitis

High specificity and positive predictive value for self-, caregiver-reported ever history of eczema

MONDAY, July 27, 2015 (HealthDay News) -- Self- and caregiver-reported history of eczema is valid for identifying atopic dermatitis (AD), according to a study published online July 17 in the British Journal of Dermatology.

Jonathan I. Silverberg, M.D., Ph.D., M.P.H., from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues performed a prospective multicenter dermatology practice-based study at three sites to examine the validity of caregiver- and self-reported ever and one-year history of eczema. Unselected patients were surveyed with questionnaires. Seven hundred eighty-two patients were then assessed by expert dermatologists.

The researchers found that, compared with a physician diagnosis of AD at that visit, caregiver-reported one-year history of childhood eczema had a sensitivity, specificity, and positive predictive value (PPV) of 0.70, 0.96, and 0.87, respectively. The corresponding values were 0.70, 0.95, and 0.76 for self-reported one-year history of adult eczema. Ever-history of caregiver- and self-reported eczema had high specificity (0.89 and 0.97, respectively) and PPV (0.81 and 0.91, respectively), with high sensitivity in children but not adults (0.83 versus 0.43).

"Self- and caregiver-reported diagnosis of eczema ever or in the past year based on a single question demonstrates sufficient validity for the epidemiological study of AD," the authors write.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.